Craif Inc. (Location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter referred to as “Craif”) has entered into a joint study agreement with Medical Corporation Omiya City Clinic (Location: Saitama, Chairman: Takashi Nakagawa, hereinafter referred to as “Omiya City Clinic”). With the conclusion of this agreement, Craif and Omiya City Clinic (Principal Investigator: Ryo Nakagawa) will begin a joint study to "Explore Biological Substances Such As Urinary microRNA (miRNA) Associated with Health Conditions, and Occurrence/recurrence of Diseases for Cancer etc."
We also value the spirit of hospitality and aim to create a better environment from the examination room to the waiting room. In terms of the facilities, we hope to be a clinic where patients can feel warmth not only by introducing the latest medical equipment, but also by providing coziness to patients.
Source:
(*1) Jiang Q et al. miR2Disease: A manually Curated Database for microRNA Deregulation in Human Disease. Nucleic Acids Res. (2009) 37: 98-104.
(*2) Hammond, S. M. (2015). An Overview of microRNAs. Advanced Drug Delivery Reviews, 87, 3-14.
(*3) Huan, T., Chen, G., Liu, C., Bhattacharya, A., Rong, J., Chen, B.H., Seshadri, S., Tanriverdi, K., Freedman, J.E., Larson, M.G. and Murabito, J.M. (2018). Age Associated microRNA Expression in Human Peripheral Blood is Associated with All Cause Mortality and Age-related Traits. Aging Cell, 17(1), e12687.
